Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 01, 2022

SELL
$3.04 - $5.14 $4,167 - $7,046
-1,371 Reduced 90.55%
143 $0
Q2 2022

Jul 13, 2022

BUY
$3.17 - $6.17 $1,527 - $2,973
482 Added 46.71%
1,514 $6,000
Q1 2022

May 13, 2022

BUY
$4.16 - $13.72 $723 - $2,387
174 Added 20.28%
1,032 $6,000
Q4 2021

Feb 14, 2022

BUY
$10.83 - $18.41 $9,086 - $15,445
839 Added 4415.79%
858 $12,000
Q3 2021

Oct 29, 2021

SELL
$13.07 - $18.84 $601 - $866
-46 Reduced 70.77%
19 $0
Q2 2021

Aug 06, 2021

BUY
$16.52 - $20.4 $247 - $306
15 Added 30.0%
65 $1,000
Q1 2021

May 10, 2021

BUY
$16.56 - $25.46 $827 - $1,273
50 New
50 $1,000
Q4 2020

Feb 09, 2021

SELL
$15.77 - $19.03 $741 - $894
-47 Closed
0 $0
Q3 2020

Nov 06, 2020

SELL
$16.59 - $24.79 $99 - $148
-6 Reduced 11.32%
47 $1,000
Q2 2020

Aug 10, 2020

SELL
$16.86 - $23.44 $505 - $703
-30 Reduced 36.14%
53 $1,000
Q1 2020

May 05, 2020

BUY
$14.47 - $27.96 $766 - $1,481
53 Added 176.67%
83 $1,000
Q4 2019

Jan 30, 2020

SELL
$15.87 - $23.12 $253 - $369
-16 Reduced 34.78%
30 $1,000
Q3 2019

Nov 05, 2019

SELL
$16.91 - $36.27 $219 - $471
-13 Reduced 22.03%
46 $1,000
Q2 2019

Aug 06, 2019

BUY
$31.0 - $36.3 $310 - $363
10 Added 20.41%
59 $2,000
Q1 2019

May 01, 2019

BUY
$31.58 - $46.35 $726 - $1,066
23 Added 88.46%
49 $2,000
Q4 2018

Jan 31, 2019

BUY
$30.43 - $56.65 $273 - $509
9 Added 52.94%
26 $1,000
Q3 2018

Oct 12, 2018

BUY
$46.46 - $68.49 $92 - $136
2 Added 13.33%
17 $1,000
Q2 2018

Aug 03, 2018

SELL
$46.25 - $104.45 $185 - $417
-4 Reduced 21.05%
15 $1,000
Q1 2018

May 02, 2018

SELL
$57.4 - $108.44 $4,132 - $7,807
-72 Reduced 79.12%
19 $2,000
Q3 2017

Oct 27, 2017

BUY
$17.79 - $24.0 $1,618 - $2,184
91
91 $2,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $244M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Parkside Financial Bank & Trust Portfolio

Follow Parkside Financial Bank & Trust and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parkside Financial Bank & Trust, based on Form 13F filings with the SEC.

News

Stay updated on Parkside Financial Bank & Trust with notifications on news.